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IMPLANTS FOR SITE-SPECIFIC DRUG DELIVERY 
Implantable drug delivery systems formulated from 
drug-polymer composites have been used recently in a 
variety of applications in which chronic administration of 
a pharmacological agent to a specific anatomic site is 
advantageous. These drug delivery systems are generally 
referred to as controlled release matrices.’ Their mecha- 
nism of drug release involves either passive drug 
diffusion, or biodegradation of the polymer matrix, or 
both. This review considers only those devices that are 
implanted at the drug target site, and not those that 
dispense drugs systemically. The  advantages of site- 
specific controlled release implants are that a substan- 
tially lower dose of the drug is required, since it is 
administered at an optimal location, and therefore the 
risks for systemic side effects are greatly reduced. 
A controlled release implant, in widespread clinical 
use, is the dexamethasone-silicone rubber matrix config- 
ured for insertion in a cardiac pacing electrode tip. Al- 
though cardiac pacemakers have been utilized for the 
past 30 years, a persistent clinical problem has been the 
time-dependent progressive increase in the pacemaker 
electrode’s electrical capture thresholds due to fibrosis. 
Dexamethasone is an antiinflammatory, antifibrotic syn- 
thetic steroid. The working hypothesis of the controlled 
release dexamethasone approach is that sustained release 
steroid administered directly to the endocardium con- 
tacting the electrode would limit acute inflammation and 
chronic inflammation, as well as the resultant scarring, 
that adversely affect electrical capture thresholds. 
Several clinical studies have demonstrated the im- 
proved pacing threshold characteristics of a steroid- 
eluting electrode. A double-blinded study2 compared the 
same electrode configuration (Medtronic, Minneapolis, 
MN) with and without steroid over a 2-year follow-up 
period. The results showed that from 2 weeks to 2 years 
the pulse duration thresholds for the steroid leads re- 
mained almost constant, while the nonsteroid cases 
demonstrated a significant rise in thresholds. A more re- 
cent double-blinded clinical study has confirmed these 
findings over a 6-month follow-up p e r i ~ d . ~  Thus, the 
steroid-eluting cardiac pacing lead represents an impor- 
tant example of an effective clinical use of a controlled 
release drug implant. 
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Controlled release implants for brain tumor chemo- 
therapy have also been recently shown to be clinically 
effective and advantage~us.~ Glioblastoma multiforme is 
the commonest type of brain tumor, and its therapy via 
neurosurgery and drug administration is at present unsat- 
isfactory. Very few patients with this tumor survive more 
than 3 months after the initial diagnosis if treated with 
conventional surgery and chemotherapy. The nitrosurea 
chemotherapeutic agent, carmustine (BCNU), has been 
the drug of choice for the systemic chemotherapy of this 
brain tumor following neurosurgical removal. However, 
this compound is very short acting and highly toxic. 
Severe systemic side effects greatly limit its usefulness. 
Recurrent glioblastoma multiforme has been the focus 
of a clinical trial of controlled release implants contain- 
ing BCNU, that are placed in the tumor cavity after 
resection. These controlled release preparations consist 
of BCNU incorporated into a biodegradable high molec- 
ular weight polyanhydride. The polyanhydride formula- 
tion contains repeating subunits of sebacic acid and 
carboxyphenoxy-propane. The biocompatibility of this 
polyanhydride preparation has been well documented; 
and the initial clinical trials with BCNU-polyanhydride 
matrix implantation have been highly successful, with a 
mean survival time of 48 weeks following reoperation. In 
addition, because of the relatively low dose of BCNU 
used in the implants, the incidence of systemic side ef- 
fects has also been reduced. At present, a multicenter 
double-blinded clinical trial is underway to further inves- 
tigate the efficacy of this new approach. 
The  high molecular weight polyanhydrides offer a 
number of therapeutic options for further enhancements 
of this strategy. For example, the biodegradation of the 
high molecular weight polyanhydrides, and accompany- 
ing drug release, can take place over durations ranging 
from days to years, depending on the molecular weight 
and precise formulation parameters. Therefore, with the 
advent of new chemotherapeutic agents, and related anti- 
cancer strategies, it may be expected that the polyan- 
hydrides will be appropriately utilized to enhance the 
treatment of a variety of localized solid tumors. In 
addition, the high molecular weight polyanhydrides have 
also been formulated as microspheres: which could be 
intravascularly injected into a tumor’s vasculature to 
further enhance chemotherapy. 
The surgical and medical therapy of osteomyelitis, as 
well as infected arthroplasties, has been fraught with dif- 
ficulty due to problems optimizing antibiotic therapy. 
Antibiotic-impregnated bone cement has been used as a 
sustained release preparation for the treatment of estab- 
lished or potential bone infection. Most often, gentam- 
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icin has been incorporated into bone cement matrices 
composed of polymethylmethacrylate derivatives. Thus, 
these base polymers serve a dual function as both bone 
cement and a controlled release matrix substrate for local 
therapy. An uncontrolled study of 27 patients with pedal 
infections treated with polymethylmethacrylate-genta- 
micin bone cement reported a 95% success rate based on 
freedom from further infection.' However, the use of 
gentamicin-containing bone cement has also been associ- 
ated with the emergence of antibiotic-resistant coagulase 
negative staphylococci. In a series of 91 patients with hip 
arthroplasties complicated by infection,' 30 patients de- 
veloped gentamicin-resistant infections following treat- 
ment with antibiotic-impregnated bone cement. Thus, 
the ultimate usefulness of antibiotic-impregnated bone 
cement remains to be established by further clinical in- 
vest igations. 
Vascular grafts and cardiac valve prostheses with con- 
trolled release antibiotic formulations, have been utilized 
only to a limited extent clinically. A resorbable collagen- 
gentamicin controlled release matrix combined with a 
vascular graft composed of expanded polytetrafluoro- 
ethylene were reported to be effective for reducing the 
incidence of shunt infections in an uncontrolled series of 
40 patients undergoing chronic hemodialy~is.~ Further- 
more, an antibiotic-controlled release system (genta- 
micin-polymethylmethacrylate) was also used in a 
perianular configuration to provide continuous antimi- 
crobial administration to the immediate vicinity of a 
mechanical cardiac valve prosthesis implant in a case of 
aortic root endocarditis." Although no information was 
provided in this case report concerning the duration of 
drug release, the patient receiving the implant was 
improved one year postoperation. 
In summary, site-specific drug implants represent a 
new and innovative therapeutic approach, which will 
very likely become of general importance for treating a 
number of localized disease processes. However, there 
is an obvious need for controlled clinical trials to evalu- 
ate efficacy. Furthermore, the controlled release systems 
described in this review are based on conventional 
pharmacologic agents. Thus, it may be expected that in 
the future site-specific controlled release will involve 
custom-synthesized agents, which may be targeted 
more precisely to the tissue or organ of interest. In 
addition, controlled release implants as drug carriers for 
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